Oric Pharmaceuticals (ORIC)
(Delayed Data from NSDQ)
$11.90 USD
+0.66 (5.87%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $11.89 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ORIC 11.90 +0.66(5.87%)
Will ORIC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ORIC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ORIC
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%
ORIC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recent Price Trend in Oric Pharmaceuticals, Inc. (ORIC) is Your Friend, Here's Why
Oric Pharmaceuticals, Inc. (ORIC) Is a Great Choice for 'Trend' Investors, Here's Why
Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock?
Other News for ORIC
ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value
Analysts Are Bullish on Top Healthcare Stocks: Oric Pharmaceuticals (ORIC), Ufp Technologies (UFPT)
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Applied Therapeutics (APLT) and Oric Pharmaceuticals (ORIC)
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
ORIC collaborates with Bayer, J&J on prostate cancer study